Envista Holdings Co. (NYSE:NVST) Receives Consensus Recommendation of “Hold” from Analysts

Envista Holdings Co. (NYSE:NVST) has received an average rating of “Hold” from the fifteen analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $20.71.

A number of equities research analysts have commented on NVST shares. Stifel Nicolaus increased their price target on Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Wells Fargo & Company began coverage on shares of Envista in a research note on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 target price for the company. Piper Sandler upped their price target on shares of Envista from $16.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Leerink Partners upgraded shares of Envista from an “underperform” rating to a “market perform” rating and lifted their price objective for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Finally, Robert W. Baird upped their target price on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st.

Institutional Trading of Envista

Institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Envista during the 3rd quarter worth approximately $31,000. GAMMA Investing LLC raised its stake in shares of Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after purchasing an additional 726 shares during the period. Huntington National Bank lifted its position in shares of Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after purchasing an additional 804 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after purchasing an additional 728 shares in the last quarter.

Envista Trading Up 2.4 %

NVST opened at $20.57 on Friday. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The firm has a market cap of $3.54 billion, a price-to-earnings ratio of -2.65, a PEG ratio of 2.83 and a beta of 1.30. Envista has a 12 month low of $15.15 and a 12 month high of $25.64. The stock has a fifty day moving average price of $19.20 and a 200-day moving average price of $18.12.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.09 by $0.03. The firm had revenue of $601.00 million during the quarter, compared to analyst estimates of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. Envista’s revenue was down 4.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.43 EPS. As a group, equities research analysts anticipate that Envista will post 0.72 earnings per share for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.